Core Points - The document outlines the information disclosure deferral and exemption management system for Aorite Pharmaceutical Co., Ltd, ensuring compliance with relevant laws and regulations while protecting investors' rights [1][2][3] Group 1: General Provisions - The purpose of the system is to regulate the deferral and exemption of information disclosure, ensuring compliance with the Securities Law of the People's Republic of China and the Shanghai Stock Exchange listing rules [1] - The company can defer or exempt disclosure of information based on its own judgment, subject to internal approval and subsequent supervision by the Shanghai Stock Exchange [1][2] Group 2: Scope of Deferral and Exemption - Information can be deferred or exempted if it involves state secrets or commercial secrets that, if disclosed, could lead to unfair competition or harm the interests of the company or others [2][3] - The definition of "commercial secrets" includes non-public technical and operational information that provides economic benefits and is protected by confidentiality measures [2][3] Group 3: Conditions for Deferral and Exemption - Information must meet specific conditions, including that it has not been disclosed, insiders have committed to confidentiality, and there has been no abnormal trading of the company's stock [3][4] Group 4: Review Procedures - The company must ensure that the number of individuals aware of the information is minimized and that no leaks occur before the information is confirmed for deferral or exemption [3][4] - The board of directors must approve any deferral or exemption requests, and the relevant documentation must be properly archived [4] Group 5: Responsibilities and Penalties - The company will impose penalties on individuals responsible for failing to disclose information that should not have been deferred or exempted, or for not disclosing information when the reasons for deferral or exemption no longer apply [5] Group 6: Supplementary Provisions - Any matters not covered by this system will be governed by relevant national laws, regulations, and the company's articles of association [7]
奥锐特: 奥锐特药业股份有限公司信息披露暂缓与豁免管理制度(2025年8月修订)